CompletedNot Applicable

Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction

Jordan450 participantsStarted 2023-09-01

Plain-language summary

A significant percentage of patients with heart failure and reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) have iron deficiency who are symptomatic. This is independently associated with bad quality of life, low functional capacity, lower quality of, life and increased mortality. The prevalence of iron deficiency in HFrEF and HFmrEF patients in Jordan has not been studied in the past.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Heart failure patients with ejection fraction \<59% (including those with with reduced ejection fraction of ≤40%, or mildly reduced EF (41-49%)) within the last 2 years. * NYHA class II-IV. * Able and willing to provide oral informed consent. Exclusion Criteria: * Age\<18 years. * Acute coronary syndrome. * Known cases of iron overload (e.g. hemochromatosis); known cases of anemia due to other causes. * Oral or intravenous iron supplements within the previous 3 months; erythropoietin stimulating agents or blood transfusion within the last 6 months. * Active clinically relevant bleeding in the investigator's opinion. * Patients with chronic inflammatory conditions (e.g. rheumatoid arthritis; Crohn's disease, etc.); active infection; and decompensated liver disease.

What they're measuring

Iron deficiency

Timeframe: From date of study enrollment until the date of first documented diagnosis of iron deficiency up to 2 weeks.

Trial details

NCT IDNCT05992116

SponsorJordan Collaborating Cardiology Group

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-15

View on ClinicalTrials.gov More Iron Deficiency trials